Laurus Labs PAT More Than Doubles in Q1 as CDMO Business Drives Record Profit, Shares Hit All-Time High
Generic pharmaceutical company Laurus Labs delivered an outstanding financial performance in the first quarter of the financial year, reporting that its Profit After Tax (PAT) more than doubled compared to the same period last year. The remarkable earnings growth was primarily driven by the company’s rapidly expanding Contract Development and Manufacturing Organization (CDMO) business, which…